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Abstract
Avipoxviruses (APVs) belong to the Chordopoxvirinae subfamily of the Poxviridae family. APVs are distributed
worldwide and cause disease in domestic, pet and wild birds of many species. APVs are transmitted by aerosols
and biting insects, particularly mosquitoes and arthropods and are usually named after the bird species from which
they were originally isolated. The virus species Fowlpox virus (FWPV) causes disease in poultry and associated
mortality is usually low, but in flocks under stress (other diseases, high production) mortality can reach up to 50%.
APVs are also major players in viral vaccine vector development for diseases in human and veterinary medicine.
Abortive infection in mammalian cells (no production of progeny viruses) and their ability to accommodate
multiple gene inserts are some of the characteristics that make APVs promising vaccine vectors. Although abortive
infection in mammalian cells conceivably represents a major vaccine bio-safety advantage, molecular mechanisms
restricting APVs to certain hosts are not yet fully understood. This review summarizes the current knowledge
relating to APVs, including classification, morphogenesis, host-virus interactions, diagnostics and disease, and also
highlights the use of APVs as recombinant vaccine vectors.
Introduction
Avipoxviruses (APVs) are among the largest and most
complex viruses known. APVs belong to the Chordopox-
virinae subfamily of the Poxviridae family [1]. They
infect and cause diseases in poultry, pet and wild birds
of many species which result in economic losses to the
poultry industry. Infections have also been reported in a
number of endangered species or species in captive-
breeding recovery programs [2-4]. APVs are transmitted
via biting insects and aerosols and are usually named on
the basis of the bird species from which the virus was
first isolated and characterized [4]. The disease, which is
characterized by proliferative lesions of the skin and
diphtheric membranes of the respiratory tract, mouth
and oesophagus has been described in avian species
[4,5]. Although APV infections have been reported to
affect over 232 species in 23 orders of birds [6], our
knowledge of the molecular and biological characteris-
t i c so fA P Vi sl a r g e l yr e s t r i c t e dt of o w l p o xv i r u s
(FWPV) and canarypox virus (CNPV) for which full-
genome sequences are available [7,8]. Currently, only
ten avipoxvirus species are listed under the genus by the
International Committee on Taxonomy of Viruses
(ICTV) [1]; Table 1. Thus, it is safe to assume that
many APVs have yet to be characterized. Recombinant
APVs have been evaluated for use as vaccine vector can-
didates against infectious diseases [7,9]. APV-vectored
vaccines are already in use in veterinary medicine
[10-14], and it is likely that such vaccines will also be
used against human diseases in the future. This fact
emphasizes the need to learn more about the molecular
characteristics of APVs, which underpins the develop-
ment of safe APV-vectored recombinant vaccines. This
review summarizes current knowledge of APVs as avian
pathogens, including classification, morphogenesis, host-
virus interactions, diagnosis, as well as issues relevant to
their use as recombinant vaccine vectors.
Definition
Avipoxviruses are large, oval-shaped enveloped viruses
whose genome consists of double stranded DNA ranging
in size from 260 to 365 kb [8]. Unlike most other DNA
viruses, APVs replicate easily in the cytoplasm of infected
avian cells which results in a characteristic cytopathic
effect (CPE) 4 to 6 days post infection depending on the
virus isolate [4]. APVs also multiply on the chorioallan-
toic membrane (CAM) of embryonated eggs, resulting in
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are sometimes focal or diffuse [15]. However, some iso-
lates, especially from the host species great tit (Parus
major), have failed to multiply on CAM of chicken
embryos [16]. APVs are the etiologic agent of disease
characterized by skin lesions in both wild and domestic
birds [4,5]. Histologically and ultrastructurally, APVs
undergo morphologic stages that are similar to other
chordopoxviruses, including the formation of intracyto-
plasmic inclusions bodies, a characteristic which has
been observed in some epithelial and mononuclear cells
of permissive hosts. APV particles can be detected and
further characterized by use of transmission electron
microscopy (TEM) [17,18].
Classification
Great discoveries made in the mid-nineteenth century
facilitated major advances in pox virology. Based on the
report by Bollinger [5] on poxvirus infected cells in
chickens, and subsequent work by Fenner and Burnet
[19], APVs and other poxviruses were classified on the
basis of original host, growth and morphological charac-
teristics in the CAM of embryonated eggs or cell cul-
tures and on clinical manifestations in different diseases
of humans, birds and animals [20] rather than on
genetic identity, which may provide both rapid and reli-
able virus identification [21-23]. These criteria have
remained the basis for subsequent classification of APVs
despite development of new molecular tools that have
the capability of resolving the issue of species specificity
of APV.
Members of the genus Avipoxvirus belong to the sub-
family Chordopoxvirinae which shares several biological
features with other poxviruses [7,8]. Currently, little is
known of the number of species within the genus.
While only ten strains have so far been identified and
classified Worldwide as APV [1], avian poxvirus infec-
tions have been reported to affect a wide range of bird
Table 1 Members of the genus Avipoxvirus and their host spectrum
Type species Hosts Latin names Mode of infection Disease confirmation References
Fowlpox virus
1a Chicken Gallus gallus E, N HP, CAM, EM, PCR/Seq [7,21,27,113]
Canarypox virus
1b Canary (several species) Serinus canarius E, N HP, CAM, EM, PCR/Seq [8,17,114,115]
Juncopox virus
1 Slate coloured Junco Junco hyemalis E GE [48]
Mynahpox virus
1 Greater hill mynahs Gracula religiosa E, N HP [116]
Psittacinepox virus
1 Parrot Amazona finschi HP,CAM [62]
Quailpox virus
1 Scaled quail Callipepla squamata N HP, CAM, EM [117]
Sparrowpox virus
1 Sparrows Passer domesticus N HP, CAM, EM, PCR/Seq [16,18]
Starlingpox virus
1 Regal starling Cosmopsarus regius N HP, CAM, EM [118]
Turkeypox virus
1 Turkey Meleagris gallopavo N HP, CAM, EM, PCR [119]
Crowpox virus
2 Hawaiian crows Corvus hawaiiensis N HP, CAM [4]
Peacockpox virus
2 Peacock Pavo cristatus N HP, CAM [120]
Penguinpox virus
2 Penguin Spheniscus demersus N CAM [59]
Pigeonpox virus Pigeon Palumbus palumbus N HP, CAM, EM, PCR/Seq [16,18]
Flamingopox virus Flamingo Phoenicopterus roseus N PCR/Seq [121]
Partridgepox virus Partridges Perdix perdix N HP, EM, PCR/Seq [122]
Sea Eaglepox virus Sea eagle Haliaeetus albicilla N HP, PCR/Seq [123]
Great titpox virus Great tit Parus major N HP, EM, PCR/Seq [18,124]
Curlewpox virus Curlew Burhinus oedicnemus N HP, EM, PCR/Seq [125]
Common buzzardpox virus Common buzzard Buteo buteo N HP, CAM, EM, PCR/Seq [126]
American crowpox virus American crow Corvus brachyrhynchos N HP [127]
Ostrichpox virus Ostrich Struthio camelus N HP, CAM [128,129]
Owlpox virus Owl Strix varia N HP, CAM [130]
Goosepox virus Canada Goose Branta canadensis N HP, CAM [15]
Magpiepox virus Magpie Pica pica N HP, CAM, EM [16]
Mockingbirdpox virus Mockingbird Mimus polyglottus N HP, EM [131]
Mode of infection: N, natural; E, experimental; HP, histopathological; CAM, chorioallantoic membrane; EM, electron microscopy; PCR, polymerase chain reaction;
Seq, sequencing and GE, genetic and antigenic characterization.
1Currently classified by ICTV as members that belong to genus Avipoxvirus.
2Currently classified by ICTVas tentative members of genus Avipoxvirus.
aComplete genome sequences exists: Fowlpox virus FP9 (plaque-purified tissue culture-adapted attenuated European virus; accession number: AJ581527) and
Fowlpox challenge virus (Animal Health Inspection Service Centre for Veterinary Biologicals, Ames Iowa; accession number: AF198100).
bComplete genome sequence exists: Canarypox virus strain Wheatley (American Type Culture Collection; ATCC VR-111).
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cificity, demonstrating an urgent need for further ana-
lyses and characterization of new isolates.
Structure
Avipoxviruses share several morphological, biochemical
and physiochemical features with other poxviruses.
Virus particles measure 270 × 350 nm and are com-
posed of an electron dense, centrally located core and
two lateral bodies that are visible in fixed and stained
ultra-thin sections. In negative stained preparations,
such as phosphotungstic acid (PTA) the membrane dis-
plays an outer-coat composed of a random arrangement
of tubules [24]; Figure 1. APV particles have been
shown to be resistant to ether, but sensitive to chloro-
form treatment [25], although resistance to both chloro-
form and ether have been reported for pigeonpox virus
and two pigeonpox virus mutants [26].
Genome
Avipoxviruses have low G+C content (30 to 40%) and
consist of a single linear molecule of double-stranded
DNA of between 260-365 kb. The central region of the
genome is flanked by two identical inverted terminal
repeats (ITRs) which are covalently linked by hairpin
loops and contains several hundred closely spaced open
reading frames [7]. The central region contains about
90-106 homologous genes that are involve in basic repli-
cation mechanisms, including viral transcription and
RNA modification, viral DNA replication, and proteins
involved in structure and assembly of intracellular
mature virions and extracellular enveloped virions [8].
In general, genes located in this region have common
molecular functions and are relatively conserved among
poxviruses [8]. This is in contrast to the more variable,
terminally located genes that have been shown to
encode a diverse array of proteins involved in host
range restriction [8].
Complete genomes of the two most studied APVs,
FWPV US (FP-challenge virus; Animal Health Inspection
S e r v i c eC e n t r ef o rV e t e r i n a ry Biologicals, Ames Iowa,
USA), FWPV-FP9 (a plaque-purified tissue culture-
adapted attenuated European virus) and a CNPV virulent
strain (Wheatley C93, American Type Culture Collection;
ATCC VR-111) have been sequenced [7,8,27]. Although
nucleotide and amino acids sequences for these two
viruses are known, the functions of some putative genes
and proteins remain to be fully assigned. Comparison of
the FP9 strain with FWPV US revealed 118 differences;
of which 71 genes were affected by deletion (26 of 1-9334
bp), insertion (15 of 1-108 bp), substitution, termination
or frame-shift [27]. FP9 strain is a derivative of European
FWPV HP1 which was obtained through over 400 pas-
sages in chicken embryo fibroblast (CEF). Analysis of
FWPV HP1 sequences at the loci in which differences
exist between FP9 and FWPV US show that 68 of 118
loci differ from the FWPV US, but were identical to FP9.
This thus indicate that more than half of the differences
between the two geographic FWPV lineages represented
differences between the parent virulent viruses FWPV
HP1 and FWPV US [27]. Further comparison of molecu-
lar data; show that FWPV and CNPV share high amino-
acid identity, significant gene-sequence rearrangements,
deletions and insertions [8]. The CNPV genome is about
80-100 kbp larger than the FWPV genomes. Both FWPV
and CNPV express cellular gene homologues with immu-
nomodulatory functions, which might be responsible for
their different virulence and host-range [8], but CNPV
shows a broader tissue tropism in permissive avian hosts
[17] than FWPV. CNPV has additional sequence of over
75 kbp, 39 genes lacking in FWPV homologues and
approximately 47% amino-acid divergence [8]. These
divergences are primarily found in the terminal non-
conserved regions [7,8]. Genes located in the non
conserved regions are more prone to mutation and
recombination and are implicated in host range, immu-
nomodulation and pathogenesis [28], and may be respon-
sible in some aspects of cell and/or tissue tropism or
perform other cellular functions [8].
Virulence genes are generally of non-conserved nature
and influence the pathological profile of viruses in an
infected host. These genes are important in viral evolu-
tion and have been used in studies to provide insight
into how some poxviruses evolve strategies to ensure
Figure 1 Negative stain EM of a characteristic FWPV-particle
propagated in baby hamster kidney (BHK) cells at 72 hour
post infection.
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traced back to discoveries made with knockout (KO)
viruses, in which a targeted disruption of a specific viral
gene produced phenotypic changes reflective of the nor-
mal biological function of its protein product. Deletions
of some non-conserved genes have also resulted in con-
ditional replication defects in specific cell types [30],
such as the demonstration of spontaneous deletion of
host range genes of vaccinia virus resulting in the com-
promised growth in the mammalian cell [31]. The K1L
and C7L genes of vaccinia virus have been shown to be
essential for completion of the replication cycle of vacci-
nia virus in human cells [32,33]. In a knockout experi-
ment, vaccina virus was unable to complete its
replication cycle in Chinese hamster ovary (CHO) cells,
since replication was aborted shortly after virus binding
and entry, at the stage of intermediate gene expression
[34]. But the insertion of another host range gene,
CHOhr from cowpox virus into vaccinia virus allowed
vaccinia virus to grow in CHO cells in which they are
normally restricted [35-37]. Through use of these tech-
niques, we now have a better understanding of the biol-
ogy of vaccinia and other poxviruses, including their
host range restriction. Although, some major advances
have been made in genome sequencing and in vitro
characterization of APVs [7,8,38,39], studies on APV
host range genes are scarce. A wide array of gene homo-
logues with likely host range functions such as NK-cell
receptors, chemokines, serine protease inhibitors and
homologues of genes involved in apoptosis, cell growth,
tissue tropism and avian host range, have been identified
in APVs, which suggests significant viral adaptation in
the avian host [7]. Molecular knockout studies that tar-
get identification and further characterization of viral
genes involved in regulation of cell proliferation, chro-
matin remodelling, virulence and apoptosis, in different
APV-infected mammalian and avian cells are needed to
better understand the tissue tropism and host range
characteristics of APVs, including the abortive infection
in mammalian cells.
Host-virus interaction
Compared to other poxviruses, such as vaccinia virus,
mechanisms that account for APV pathogenesis is
poorly understood. APVs have evolved a variety of ele-
gant mechanisms to deliver their genes and accessory
proteins into host cells. Like many other DNA viruses,
APV probably devotes much of its genes to allow it to
evade host immune responses. Such viral genes com-
monly encode proteins that are critical for the virus to
undergo molecular transformation that leads to success-
ful membrane fusion, penetration and intracellular
transport. These includes genes that encodes proteins
which act on early innate pathways such as pathways
involving interferon [40], pattern recognition receptors
as Toll-like receptor (TLR) [41], chemokines [42] and
cytokines [43], as well as pathways that act on subse-
quent adaptive responses [44,45]. The infection of a cell
by a virus is a complex process, during which the virus
must overcome several host factors restriction points
and the host immune response. Host protein interaction
networks and biochemical pathways are in most cases
altered by the viral proteins that free the virus from nor-
mal cellular controls and allow nucleotide metabolism in
cells that have shut down DNA synthesis [46]. Hence,
understanding viral protein functions and their interac-
tions with host proteins is a prerequisite, not only to
understand the infection biology of the virus-host sys-
tem in question, but also for the rational development
of target vaccines, based on specific antigens and possi-
bly immunomodulatory factors, as well as antiviral
compounds.
Replication
Since the first isolation of APVs in cell culture, these
viruses have been recognized as highly host specific.
They are believed to replicate only in avian cells, notably
chicken embryo fibroblasts (CEF; American Type Cul-
ture Collection; ATCC, Rockville, Maryland, USA; CRL-
1590) [47]. CEF cells have a good split ratio compared
to other cell lines, and are thus useful for large-scale
propagation of virus, such as antigen production for vac-
cines or as a diagnostic tool. APVs have also been
shown to replicate in chicken embryo kidney, chicken
embryo dermis [48,49] and quail cell lines, such as QT-
35, although the presence of viable endogenous herpes-
virus and Marek’s disease virus (MDV) in QT-35 cells,
limits their use for preparation of vaccines [4,50]. APV
have been isolated once from a mammal. In 1969, viable
FWPV was isolated from a terminally ill rhinoceros [51].
The isolate was identified as atypical FWPV, based on
pathological, virological and serological characteristics
[51]. Nelson (1941) [52] reported mild pathology in
mice following intranasal inoculation with FWPV, with
no virus replication. Recent studies have also shown
replication of APV in mammalian cell cultures, such as
embryonic bovine tracheal cells [53] and baby hamster
kidney cells [54] that are defined by the presence of
infectious viral particles and CPE. These studies raise
questions about the species specificity and mechanisms
that restrict these viruses to certain hosts, and challenge
the hypothesis that APV cannot undergo a full replica-
tion cycle in mammalian cells.
Morphogenesis
The cellular entry and exit of APV is complicated by the
existence of at least two distinct forms of virus that can
productively infect cells, namely the intracellular mature
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These two forms are surrounded by different lipid mem-
branes and surface proteins that are yet to be fully
characterized.
After virus binding to cellular membranes, a fusion
step, which is generally poorly understood, results in the
release of the virion core into the cytoplasm of the cell
[39]. The released core, which contains the endogenous
RNA polymerase and transcription factors, initiates the
first wave of early viral gene transcription by synthesiz-
ing viral mRNA under the control of early viral promo-
ters. This is followed by the uncoating stage, the release
of viral DNA into the cytoplasm where it serves as a
precursor for viral DNA replication as well as the source
of intermediate and late viral gene transcription. As a
late viral gene product accumulates, the virus undergoes
assembly and morphogenesis of infectious virus parti-
cles. During morphogenesis, APVs induce the formation
of inclusion bodies in the cytoplasm of infected cells
(Figure 2A and 2B). The inclusions, which may also be
termed viral factories, viroplasms, or viral replication
complexes, are generally believed to be the sites of
active viral replication and particle assembly within
infected cells [17]. One model for the function of viral
inclusion bodies is that they act to concentrate and
sequester proteins, nucleic acids, and other small mole-
cules essential for viral processes.
In permissive cells, the first viral structures detect-
able by electron microscopy are the crescent-shaped
forms (Figure 3A), consisting of a membrane with spi-
cules on the convex surface [39]. These structures
develop into non-infectious spherical immature viruses
(IV) (Figure 3B) from which the intracellular mature
virus (IMV) is formed by a series of maturation steps
(Figure 3C). The IMV represents the majority of infec-
tious progeny from each infected cell [17,39,55]. There
are three possible mechanisms by which poxviruses are
released from host cells depending on the strain of
virus, cell type and the post-infection time [54-56].
They can be released by cytolysis, in which case IMV
are released when the cell undergoes lysis as a result
of CPE at the advanced stage of infection. It can also
be released via virus-induced exocytosis. The third way
o fr e l e a s ei sb yb u d d i n g ,i nw h i c hc a s eI M Vm i g r a t e s
out of the virus factory through the plasma membrane.
Budding is shown to be the main exit route for APV
[39] in contrast to the orthopoxviruses which exit by
exocytosis of intracellular enveloped virus (IEV) [57].
These exit processes all result in the acquisition of an
additional double membrane [39,55]. In non-permissive
African green monkey cells (CV-1, Vero) and in a
human cell line (MRC-5), there is a blockade of the
APV morphogenesis cycle. This occurs in steps follow-
ing the formation of immature virus and is shown to
be devoid of an alteration in early gene expression
[47,58,59], indicating that this blockade may not be
associated with cell receptors.
Poxvirus tropism may not be dependent upon specific
cell surface receptors, but rather upon the ability of a
given cell to provide intracellular complementing factors
needed for productive virus replication, and on the abil-
ity of the specific virus to successfully manipulate intra-
cellular signaling networks that regulate cellular antiviral
p r o c e s s e sf o l l o w i n gv i r u se n t r y[ 2 8 ] .A P V sh a v el a r g e
Figure 2 A and B Transmission electron microscopy (TEM) of FWPV-infected (A) bird skin tissue showing outer layers of epidermis,
with typical inclusion bodies (Bollinger bodies) in the dermis (bar = 20 μm) and (B) cells with characteristic intracytoplasmic inclusion
bodies containing viral particles (bar = 2 μm).
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lections of viral proteins that function as host range fac-
tors, which specifically target and manipulate host
signaling pathways to establish optimal cellular condi-
tions for viral replication. However, in some cells, espe-
cially mammalian cells, APV replication is blocked. This
may be due to the ability of APV to specifically activate
signalling pathways or mediators, for example interferon
pathways, in those cells. The role of mediators and
immunopathology of APV is complex and not well
understood. However, considering the numerous steps
involved in APV morphogenesis, it is relevant to note
that these viruses induce several mediators that allow
them to survive and interact with the host cells. Some
potential mediators have been identified [7] and are
awaiting proper functional characterization. These mole-
cules alone may not fully explain the events that have
been documented in mammalian cells that have sup-
ported the replication of APV [54]. Hence, identification
of new mediators that are up or down-regulated in
response to APV infected mammalian and avian cells
could help advance our knowledge of immune responses
against APV and the related immune-mediated pathol-
ogy and cell tropism. It would be of vital importance to
investigate these characteristics further, especially for
the cell types that were recently shown to support APV
replication [53,54].
Pathogenicity
APV infections are associated with significant levels of
morbidity and mortality in domestic and wild bird popu-
lations [6,60]. Most of the investigations and reported
cases are based on single APV isolates, which makes it
difficult to address the pathogenicity of different APVs in
different bird species. Chickens are commonly used to
determine the pathogenicity of new isolates, but chickens
may not be the ideal host, since APVs from wild birds
may not multiply in chickens. In an attempt to identify
and characterize the pathogenicity of APVs, Tripathy and
others [4] found that wild isolates of Hawaiian crowpox
virus had a generally mild pathogenicity in domestic
chickens, characterized by relatively minor lesions of
short duration at the sites of inoculation, which were in
contrast to the general ability of FWPV strains to pro-
duce extensive proliferative lesions [4]. In another experi-
mental study, two APV isolates obtained from
endangered Hawaiian wild birds, the Hawaiian Goose
(Branta sandvicensis)a n dt h eP a l i l a( Loxioides bailleui),
were compared with FWPV in specific-pathogen-free
chickens. Immune responsesw e r em e a s u r e db yE L I S A
before and after immunization with Hawaiian APVs and
after challenge with FWPV. Both isolates from Hawaiian
birds developed only a localized lesion of short duration
at the site of inoculation in chickens and did not provide
protection against subsequent challenge with virulent
FWPV, in which severe lesions were observed. In con-
trast to high antibody response in chickens immunized
with FWPV, birds immunized with either of the two
Hawaiian isolates developed low to moderate antibody
responses against viral antigens [61]. Pathogenicity stu-
dies of APVs in parrots [62], turkeys, pigeons and can-
aries have also been reported. Canaries were highly
susceptible to CNPV, but showed resistance to turkeypox
virus, FWPV and pigeonpox virus [4,63,64]. A poxvirus
from a Canada goose (Branta canadensis) was transmis-
sible to domestic goose, but not to chickens or domestic
ducks [15]. Pigeonpox virus produced mild infection in
chickens and turkeys, but was more pathogenic for
pigeons [62]. Poxvirus isolates from magpies (Pica pica)
and great tits (Parus major)d i dn o ti n f e c ty o u n g
Figure 3 A, B and C Virion morphology of avipoxviruses in chicken embryo fibroblast cells (CEF). (A) Electron microscopy showing
crescent-shaped structures consisting of a membrane with spicules on the convex surface, (B) spherical non-infectious immature viruses (IV)
which give rise to formation of (C) intracellular mature virions (IMV) by a series of maturation steps.
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backed magpie (Gymnorhina tibicen) produced lesions in
chickens. These studies were based on clinical manifesta-
tions in the chickens and suggest host specificity and
pathogenicity.
Despite the worldwide prevalence of APV infections,
experimental infection studies in birds using APVs have
centred on relatively few viral isolates. Analyses of varia-
tion have essentially focused on a FWPV strain termed the
prototype, while a minority of experimental studies have
been reported on CNPV, quailpox, juncopox, and pigeon-
pox virus isolates [4,48,49]. In fact, in the last twenty years,
approximately 50% of published studies on APVs have
been on the FWPV isolate directly (based on a PubMed
search on APVs). The important nature of APVs which
has been used successfully for vaccine development man-
dates that a larger pool of viral strains should be analyzed
both for consideration of pathogenesis and determination
of immune correlates of protection.
Antigenic and genetic variability among APVs
Our present understanding of the antigenic variation of
APVs has been based on a limited number of virus iso-
lates in assays that includes complement-fixation, passive
hemagglutination, agar-gel precipitation, immunoperoxi-
dase, virus neutralisation and immunofluorescence
[48,49,65]. In addition to the immunological assays, varia-
tion of APVs has also been addressed through genetic
assays, such as restriction enzyme analysis. Genomes of
FWPV and quailpox virus isolates were compared by
using BamHI, EcoRI, and HindIII endonucleases and dis-
tinct fragment patterns were observed between the iso-
lates. The patterns of three quailpox virus isolates were
similar to each other with a high proportion of co-
migrating fragments. However, when immunogenic pro-
teins of three FWPVs, two quailpox viruses, a juncopox
virus, and a pigeonpox virus isolates were examined by
i m m u n o b l o t t i n g ,s h a r e da sw e l la su n i q u ea n t i g e n sw e r e
detected. The greatest disparity was observed between
quailpox virus and FWPV [48,49], indicating extensive
variation between the quailpox virus and FWPV, which
would predict differences in immunogenicity and antige-
nicity, including neutralization sensitivity. Nucleotide
sequence based studies for rapid identification of pox-
virus species by PCR with specific primers and hybridisa-
tion are well established [21]. These approaches have
concentrated on single genes or portions of genes that
exhibits variations in their sequence and are important
for quick analysis of genetic variability [22].
Phylogeny
Understanding the phylogenetics of APVs is essential to
the understanding of host specificity and virulence, but
also to provide insights into the variation of different
viruses. Although the complete genome sequences of
FWPV and CNPV are available [7,8], little is known
about APV phylogeny. This is probably because of the
difficulty in identifying pan-genus or species-specific PCR
primers that can be used to amplify different genes. The
most common PCR locus used until now has been the
P4b locus [21]. Recent phylogenetic studies of APV iso-
lates based on this locus [22,23] indicated that most iso-
lates clustered around either CNPV or FWPV, while
another study based on the same locus demonstrated a
third cluster, from psittacine birds [66]. Amano and cow-
orkers [38] showed that the CNPV thymidine kinase
locus was highly diverged from that of FWPV. The extent
of this divergence was further illustrated by the fact that
the amino acid similarity between CNPV and FWPV
orthologue P4b was only 64.2% [23,38]. A recent study,
based on three different genes including the P4b, revealed
that penguinpox virus, isolated from lesions around the
eyes of African penguins (Spheniscus demersus), was
most closely related to turkeypox virus, ostrichpox virus
and pigeonpox virus [67].
Diseases
During avipox outbreaks, mortality can reach 80 to
100% in canaries and other finches. This is in contrast
to a generally lower mortality seen in chicken and tur-
key [60]. Transmission of virus can occur through a
break in the skin or, more commonly, when vectored by
biting insect such as mosquitoes and mites [68]. Aero-
sols generated from infected birds, or the ingestion of
contaminated food or water have also been implicated
as a source of transmission [69]. The disease is most
commonly characterized by cutaneous proliferative
lesions consisting of epithelial hyperplasia of the epider-
mis that resulting in proliferative, wart-like projections.
They are primarily confined to unfeathered parts of the
body, such as legs, feet, eyelids and the base of the beak
(Figure 4). Scars are usually visible after recovery and
healing of skin lesions. The mortality in wild birds is
usually low, depending on the number and size of the
proliferative lesions. However, if infection occurs in
feather-free areas of the skin, with secondary bacterial
infection, mortality may be high. The other and less
common form of APV infections is the diphtheritic or
wet form [70] which occurs as fibrino-necrotic and pro-
liferative lesions in the mucosa of the digestive and
upper-respiratory tracts, and generally has a higher mor-
tality than the cutaneous form [60]. In some instances,
birds display both cutaneous and diphtheritic forms and
in those cases, mortality rates are often higher compared
to the cutaneous form alone. Despite the variety of hosts
and virus strains, associated pathology remains the same
in infected domestic birds, although clinical signs vary
depending on the virulence of the virus, susceptibility of
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exist a relationship between FWPV and the avian retro-
virus, reticuloendotheliosis virus (REV) (see section on
APVs and REV). However, the possible roles that simul-
taneous REV infection arising from the provirus integra-
tion into the FWPV genome might play in the
expression FWPV during disease outbreak remain unre-
solved. It is well known that REV infection leads to
immunosuppresion [71] in affected birds. Thus, it is
plausible to suggest that the presence of REV in FWPV
infection may exacerbate disease progression. In spite of
the fact that some mammalian cell lines seems to be
able to support the replication of APVs, there is no evi-
dence that APVs have caused clinical disease in humans,
in contrast to what is known for other poxviruses, such
as several parapox and orthopoxviruses.
Diagnosis of APV infections
Clinical diagnosis
Clinical features of infected birds show multiple skin
lesions varying from papules to nodules. Gross lesions
in both the cutaneous and the diphtheritic forms, seen
on birds and during necropsy, are usually sufficient to
suspect APV infection [60]. However, these signs are
sometimes not sufficient for definitive diagnoses of APV
infection as other agents, such as papilloma virus, scaly
leg mites [72] and mycotoxins may produce similar
lesions in the skin [60], and conditions like candidiasis,
capillariasis and trichomoniasis may give lesions in the
oral cavity similar to the diphtheritic form of APV
infection [73]. It is therefore crucial to secure samples
and confirm the viral etiology of the condition.
Laboratory diagnosis
Histopathology and electron microscopy
Suspicion of clinical signs of APV infection can if possible
be supported by necropsy, especially if the oral cavities to
reveal the diphtheritic form. Further, histopathology on
tissue sections using the classic Wright’s Giemsa stain
may reveal typical large, solid or ring-like, eosinophilic
intracytoplasmic inclusions known as Bollinger bodies [5];
Figure 2A and 2B. Transmission electron microscopy
(TEM) may also reveal definite proof of APV infection,
demonstrating the typical APV particles within inclusion
bodies. APV identification may also be carried out by
negative staining electron microscopy with 2% phospho-
tungstic acid (PTA) on infected cells (Figure 1). This
method has typically been used by national reference or
research laboratories to identify APV [18].
Virus isolation
Demonstration of infectious virus by inoculation of
homogenates of clinical samples of typical APV skin
lesions onto the CAM of embryonated hen’se g g si st h e
gold standard method for diagnosis of APV, although
some strains of APV do not grow readily on chicken
embryos [16]. Eggs are first swabbed with 70% alcohol
and a pore is made in an area over the air-cell and
another one on the other side of the egg to make a false
air sac and lower the CAM by negative pressure using a
rubber bulb. Inoculation of infectious samples by the
Figure 4 Avipoxvirus infection of a great tit (Parus major) (left) and a common magpie (Pica pica) (right). The protecting feather coat is
destroyed. Proliferative lesions and crust are seen, with secondary bacterial infection (Photo: Gunnar Holt, National Veterinary Institute, Oslo,
Norway).
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syringe with approximately 0.1-0.2 mL of inoculum.
Eggs are incubated at 37°C for 5 days with daily cand-
ling to check for embryo death. Pock lesions measuring
in size 0.5-1.5 mm are observed on the membrane
3-5 days after inoculation, depending on the virulence
of the virus [15,16]. Another method of isolation of
APV requires the excision and homogenization of clini-
cal skin lesions and inoculation of a homogenate super-
natant onto a permissive cell culture, such as CEF cells.
This results in the formation of CPE within 4-6 days
post inoculation, depending on the virus isolate and on
the multiplicity of infection (MOI) [4].
Molecular techniques for detection and characterization
APV are increasingly being detected and characterized by
PCR, Restriction fragment length polymorphism (RFLP),
Southern blot hybridization, and cycle sequencing, direc-
ted at specific genes such as the 4b core protein gene
[22,23]. PCR allows for sensitive and specific detection of
viral nucleic acids and has been shown to increase the
diagnostic sensitivity for many viral pathogens when
compared to culture. A PCR amplicon sequence allows a
rapid search for homologous sequences in gene data-
bases, to verify and identify the virus in question and to
address phylogenetic relationships. Detection by real-
time PCR has been used to identify recombinant APV
from individual plaques [74]. This method eliminates the
need for amplification and hybridization from the transi-
ent dominant protocol and results in significant savings
of time at each round of plaque purification [74].
Serological assays
The conventional serological techniques of passive neu-
tralization and agar-gel immunodiffusion are in contin-
ued global use for surveillance and disease control
efforts in domestic poultry species [75,76], despite the
availability of modern molecular and immunoassay tech-
niques. The tests are time consuming, especially when
carried out with large numbers of sera, and sensitivity
appears to be low when compared with other detection
method, such as enzyme linked immunosorbent assay
(ELISA) [77]. ELISA has been described as a non-species
specific test approach for birds [78]. It is a faster and
easier method to detect antibodies against APV, particu-
larly when large numbers of sera are to be tested. The
technique is also more sensitive than the neutralization
test [18,78]. ELISA protocols have also been developed
and used to test the efficacy of FWPV vaccines in com-
mercial and wild bird species where agar-gel immuno-
diffusion is ineffective due to lack of precipitating
antibodies [61,79].
Prevention and treatment
The challenges of controlling APV disease in poultry are
driven by economics, and require strategies that keep
cost low while maintaining treatment efficacy. Prophy-
laxis can be achieved by vaccination [39]. Doyle [80]
reported the use of live FWPV or Pigeonpox virus for
vaccination against APV infection. Since then, recombi-
nant and live modified vaccines have been developed
and used to prevent APV infections in chickens,
pigeons, turkeys and quails [79,81,82]; Table 2. These
vaccines are very effective and have undoubtedly con-
tributed immensely to the prevention of the disease in
commercial poultry farming [47,81]. Since different
APVs are isolated from a wide range of bird species and
since only a few isolates have been characterized, devel-
opment of a taxon-specific vaccine, directed to all spe-
cies, has been difficult. Thus, available vaccines are
often applied on the basis of experimentation, and more
knowledge of molecular biology, pathology and epide-
miology of these viruses is necessary to develop vaccines
that effectively can protect a range of bird species. As in
most viral infections, there is no specific treatment for
avian poxvirus infections in birds [39,83]. Available
treatments include the use of iodine-glycerin application
on proliferating skin lesions to aid healing [84], antibio-
tics to control secondary bacterial infections and vitamin
A to aid healing [85].
Avipoxviruses and reticuloendotheliosis virus
(REV)
In the poultry industry, prophylactic measures against
FWPV are achieved primarily by vaccination with live
FWPV or antigenically similar pigeonpox virus strains
produced in CEF cells [60]. In the past two decades,
numerous outbreaks have been reported in vaccinated
flocks, suggesting that vaccines used against the disease
were not effective. In the United States a commercial
FWPV vaccine was shown to be contaminated with REV
and caused lymphoma among broiler chickens [86]. It
has been shown that sequences of REV have been inte-
grated into the DNA of FWPV vaccines as well as in field
FWPV isolates [81,87-90]. The integration site is con-
stant, while the size of the integrated fragments differs
between various isolates and strains. Two different types
of integrated sequences are reported; long terminal
repeats (LTRs) with size of approximately 200 to 600 bp
and the near-full-length REV provirus of about 800 bp
[87,90,91]. Most vaccine strains carry only an LTR
remnant while most FWPV field isolates carry the near-
full-length provirus. Singh and others [81], however,
detected REV LTRs of various lengths in the genome of
two commercial FWPV vaccine strains and four field iso-
lates, while several studies have shown that the source of
REV infection was REV-contaminated FWPV [86,92-94]
and herpesvirus of turkeys vaccines [92,94-97]. Reticu-
loendotheliosis is a tumorigenic and immunosupressive
disease. REV strains have been reported to cause diseases
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lesions and a runting-stunting syndrome in chickens, tur-
keys, and quails [98,99]. REV are group of avian retro-
viruses and representatives include the defective REV-T
and the non-defective REV-A, spleen necrosis virus
(SNV), duck infectious anemia virus, and chick syncytial
virus (CSV) [98]. The presence of REV in FWPV vaccines
and the failure of currently used FWPV vaccines to evoke
high level immunological protection against field chal-
lenge of FWPVs are of major concern to the poultry
industry [100], which emphasizes the need for research
into alternative vaccines.
Avipoxviruses as vaccine vectors
In 1796 Edward Jenner [101] published his landmark
findings that vaccination of humans with cowpox virus
could prevent infection with variola virus, the causative
agent of smallpox [101,102]. This traditional vaccine
technology, based on live viruses and immunological
cross protection, has given rise to a wide range of effec-
tive vaccines against a wide variety of infectious agents,
both in veterinary and human medicine. However, the
emergence of new deadly human pathogens and cancers,
have proven less amenable to the application of tradi-
tional vaccine platforms, indicating the need for new
approaches. The use of a live virus vector represent an
attractive way to deliver and present vaccine antigens
that may offer advantages over traditional platforms, by
improving the quality and strength of the immune
response, such as in the case of HIV-1 where two differ-
ent strains of vaccinia virus have been used as vectors.
The NYVAC vector has been shown to induce the CD4
+ T cell-dominant response, whereas modified vaccinia
virus Ankara (MVA) induces a stronger CD8
+ Tc e l l
response with accompanying CD4
+ T cell responses that
are required for protection [103]. Although this asser-
tion remains unproven (there are to date no virally vec-
tored vaccines licensed for human use), virally vectored
vaccines offer an avenue of possibilities, either as homo-
logous regimens, or as heterologous (prime-boost) regi-
mens in which different serotypes of a given vector,
different vectors or vectors and traditional technologies
such as recombinant protein in adjuvant are adminis-
tered sequentially.
Currently, representatives of a wide range of virus
families are under intensive development as vaccine vec-
tors for human or veterinary use. Of these, FWPV and
CNPV appear to be of great interest as vectors, and
some veterinary APV-vectored vaccines are already
licensed and in commercial use in North America,
South America and Europe (Table 2). The most impor-
tant characteristics of APVs as vaccine vectors are that
unlike most other DNA viruses, APV replicate in the
cytoplasm of the infected cell and enzymatic functions
used for transcription and replication are provided by
the virus itself. This has several consequences regarding
the use of these viruses as vaccine vectors. For example,
APV promoters must be used for efficient transcription
of recombinant genes and as APV transcripts are not
spliced, genes cloned into APV vectors cannot contain
introns [70,104]. Other reasons include (1) their ability
to accommodate and effectively express large amounts
of foreign DNA or multiple genes that encode antigens
[47], (2) their inability to conduct a full replication cycle
in non-avian species [105-107], (3) antisera against
orthopoxviruses do not neutralize APV and thus, prior
Table 2 Avipoxvirus vector-based vaccines licensed for commercial veterinary use
Recombinant viral vector Inserts Targeted Pathogen Species Distributor Country References
ALVAC G Rabies virus Cats Merial, Inc. USA, Canada [109]
ALVAC HA and
F
Canine distemper virus Dogs,
ferrets
Merial, Inc. USA, Argentina, Brazil,
Colombia, Canada, Uruguay
[132]
ALVAC PrM-E West-Nile virus Horses Merial, Inc. USA, Canada [133,134]
ALVAC Env,
Gag/
pol
Feline leukaemia virus Cats Merial, Inc. Europe, USA, Canada [135-137]
FWPV H5 HA Avian influenza virus Chickens Merial, Inc. USA, Canada [110]
ALVAC (plus tetanus toxoid
and Carbopol adjuvant)
HA Equine influenza virus Horses Merial, Inc. Europe, USA [111]
FWPV HN
and F
Newcastle disease virus Chickens Biomune USA [13,138]
FWPV- Laryngotracheitis
Vaccine
LT+AE Infectious Laryngotracheitis
virus
Chickens Biomune Co.
(Lenexa, KS, USA)
USA [139]
FWPV- Mycoplasma
gallisepticum Vaccine
MG+AE Avian Encephalomyelitis and
Mycoplasma gallisepticum
Chickens Biomune Co. USA [140]
Note: HA from influenza virus H5; HA, hemagglutinin; HN, haemagglutinin-neuraminidase protein; ALVAC, attenuated canarypox virus; FWPV, fowlpox virus; F,
fusion protein; G, glycoprotein G; Env, envelope glycoprotein; Gag, group specific antigen; Pro, protease; prM-E, pre-membrane and envelope proteins; MG+AE,
Mycoplasma gallisepticum + Avian Encephalomyelitis; LT+AE, Laryngotracheitis virus+Avian Encephalomyelitis.
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smallpox) and exposure to other orthopoxviruses such
as cowpox virus does not impact the immunogenicity of
FWPV and CNPV vectors, and (4) the fact that FWPV
and CNPV do not elicit high levels of neutralizing anti-
bodies, which means that their vectors can be used mul-
tiple times without the diminished potency usually seen
with repeated use of vaccinia virus vectors. This attri-
bute is of crucial importance for a therapeutic vaccine,
requiring repeated booster shots [108].
APV-vectored vaccines have been used as vaccines
against several animal infections including West Nile
virus (WNV), canine distemper virus, feline leukemia
virus, rabies virus, and equine influenza virus [109];
Table 2. Notably among them is the Trovac AI H5, a
recombinant FWPV that express the H5 antigen of avian
influenza virus. This product has had a conditional
license for emergency use for chickens in the United
States since 1998 and has been widely used in Central
America, with over 2 billion doses administered [110].
ALVAC vectored vaccines have recently been registered
for veterinary use in the European Union (Proteq-Flu)
[111] and the United States (Recombitek). The equine
influenza virus vaccine with CNPV vector expresses the
hemagglutinin genes of the H3N8 Newmarket and Ken-
tucky strains and contains a polymer adjuvant (Carbopol;
Merial Ltd.). With the induction of both cell-mediated
and humoral immunity, it is claimed that the vaccine
produced sterile immunity 2 weeks after the second of
two doses. The new vaccine is also designed to protect
horses against the highly virulent N/5/03 American strain
of equine influenza virus and to prevent the virus from
spreading through the elimination of viral shedding.
Despite these notable advances in APV-vectored vac-
cine development, the list of licensed viral vectored vac-
cines for human medicine is short, with only a few
vaccines that have entered clinical trials [112]; Table 3.
This may be in part owing to stringent safety require-
ments that must be met for viruses, that in their natural
state have the potential to be human pathogens, to be
used as viral vaccine vectors that may replicate in vivo
in a manner similar to their wild-type parental viruses.
Another reason may be fear of risk of spontaneous
recombination between virus vectors and naturally
occurring viral relatives in the ecosystems in which the
vaccine is used. Even if APVs are not generally expected
to replicate in mammals, the vaccine vectors may reach
bird populations via animal populations. It is also possi-
ble that the vector, through spontaneous recombination
and mutation events, may restore its replication compe-
tence. To cater for this, the aim during design and
development of a virus vector is always to introduce at
least two gene deletions crucial for viral to undergo a
full replication cycle to as s u r eav e r yl o wp r o b a b i l i t y
that replication competence could be restored. To our
knowledge, such reversions have not been identified in
clinical trials of APV-vectored vaccines. In addition to
concerns regarding reversion or recombination, another
safety signal was recently identified in an in vitro experi-
ment that showed APV replication in cell clones derived
from embryonic bovine trachea [53] and Syrian baby
hamster kidney (BHK) cells. In this experiment, infec-
tious IMV was observed; indicating complete virus repli-
cation had taken place [54]. These findings are in
contrast to the general dogma that APVs are restricted
to infection of cells of avian origin, and are an indication
that there is still more to learn about the replication
mechanisms and virus-host interactions of these viruses,
including evasion of immune responses, cell tropism
and host range mechanisms.
Conclusions
APVs cause disease of economical importance for the
poultry industry, and also in pet and wild birds. Thus,
Table 3 Avipoxvirus vector based vaccines and prime-boost immunization regimes in clinical development for
human use
Recombinant viral vector Targeted
pathogen/
disease
Inserts Vaccine details Developer/Sponsors Clinical
phase
References
ALVAC containing the gene
encoding HIV-1 gp160, and
protein gp120
HIV-1 gp160 and gp120 ALVAC-HIV vCP1521 prime
and AIDSVAX-gp120 subtype
B/E boost
U.S. Army Medical
Research and Materiel
Command
III [141]
ALVAC-HIV (vCP1452) and LIPO-
5+vCP1452
HIV-1 LIPO-5 ALVAC-HIV (vCP1452) LIPO-5 NIH I/II [142]
VACV and ALVAC or FWPV with
or without combination therapy
Cancer CEA
(pancarcinoma)
TRICOM vectors co-express
B7.1, ICAM1 and LFA3
NIH I/II [143]
FWPV (FP9) Malaria Circumsporozoite
(CSP) protein
Attenuated FP9 and
Circumsporozoite (CSP)
protein
Gates Malaria
Partnership
I [144]
HIV-1, human immunodeficiency virus 1; ALVAC, attenuated canarypox virus; gp160, glycoprotein 160; gp120, glycoprotein 120; VACV, vaccinia virus; FWPV,
fowlpox virus; CEA, carcinoembryonic antigen; TRICOM, triad of costimulatory molecules; ICAM1, intercellular adhesion molecule 1; LFA3, lymphocyte function-
associated antigen 3; LIPO-5, Lipopeptide 5; CSP, circumsporozoite protein; FP9, attenuated fowlpox virus 9; NIH, US National Institutes of Health.
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required, and there is a need for more efficient and safe
vaccines. One promising approach is the use of APVs as
vectors for recombinant vaccines, increasing the efficacy
and avoiding the potential contamination with REV and
other agents. Many recombinant APV constructs are
already licensed for use in veterinary medicine, and a
range of vaccine candidates are currently being tested for
use in vaccines against numerous infectious diseases in
animals and man. Thus, it is likely that recombinant
APV-vectored vaccines in the near future will also be
used against human diseases. APVs have many advan-
tages as vaccine vectors, including a large genome which
allows for the inclusion of many heterologous genes,
such as genes coding for antigens, cytokines and other
immuno-modulating factors. The major safety argument
for using APVs rather than vaccinia virus or other mam-
malian viruses as vectors, is that APVs are not zoonotic
and are not able to conduct a full replication cycle in
mammals. However, it was recently shown that FWPV
was able to replicate and produce progeny virions in
some established mammalian cell lines. This illustrates
the fact that general knowledge of APVs is scarce.
Indeed, only a few isolates have been characterized and
classified. New molecular tools have led to a greater reso-
lution of factors and mechanisms that restrict viruses to
certain hosts, for example HIV and SARS. Mechanisms
of host restriction, pathogenicity, host immunity and
viral immune evasion strategies are of crucial importance
regarding use of APVs as vectors in multispecies-targeted
vaccines. A good understanding of the molecular proper-
ties of APVs underpins the development of safe APV-
vectored vaccines.
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